Glenn J. Hanna. M.D. is Director of the Center for Salivary and Rare Head and Neck Cancers, and Director of the Center for Cancer Therapeutic Innovation (CCTI), the early drug development program at Dana-Farber Cancer Institute. Board-certified in medical oncology and internal medicine, he is also Associate Professor of Medicine at Harvard Medical School.

Dr. Hanna's clinical and translational research efforts are focused on both molecular and immunologic biomarker discovery to foster precision medicine approaches to treat head and neck cancers and improve patient outcomes. He maintains foundation and industry support to explore immuno-oncology approaches to treat head and neck cancers and high-risk oral precancerous lesions using novel combination immune checkpoint blockade, intra-tumoral injectables, and immune effector cell (IEC) therapies. He has additional interest in precision medicine approaches to treat salivary cancers of the head and neck, and in using cell-free DNA to treat and monitor human papillomavirus (HPV)-associated head and neck cancers.

Dr. Hanna completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute. He earned his medical degree from Georgetown University School of Medicine, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He completed his residency at Beth Israel Deaconess Medical Center in Internal Medicine.